I
IASO Biotherapeutics
Biotech & Life Sciences · China · Founded 2017
Focused on the discovery, development and commercialization of cell therapies in the field of oncology MoreLess
IASO Biotherapeutics, founded in 2017, is a clinical-stage biopharmaceutical company specializing in the development and commercialization of cell therapies for oncological and autoimmune diseases. The company's core focus is on Chimeric Antigen Receptor (CAR)-T cell therapies, with a pipeline that includes candidates for various conditions.
A key product in their portfolio is Equecabtagene Autoleucel (also known as CT103A), a fully human BCMA CAR-T therapy for the treatment of relapsed/refractory multiple myeloma (RRMM). The company has presented data showing promising efficacy for this treatment. Beyond oncology, IASO is exploring the application of its cell therapies in autoimmune diseases, with studies underway for conditions such as multiple sclerosis (MS).
The company manages the entire lifecycle of its therapies, from initial discovery and development to manufacturing and eventual commercialization. It has received Investigational New Drug (IND) application approvals from regulatory bodies, including the FDA in the United States, allowing it to conduct clinical trials and advance its therapeutic candidates.
Keywords: cell therapy, biopharmaceutical, CAR-T, multiple myeloma, multiple sclerosis, oncology, autoimmune diseases, clinical-stage, BCMA, Equecabtagene Autoleucel
Company overview
IASO Biotherapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- China
- Employees
- 50
- Open positions
- 2
- Dealroom signal
- 86.9
Valuation & funding
IASO Biotherapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| FundingOther financing | Jul 2024 | $0 | — | Innovent Biologics | ↗ |
| SERIES COther financing | Jan 2023 | $74M | $540M | Guoxin Investment · Houxin Jiantou Private Equity Fund Management · Hongcheng Capital · Shanghai Wai Gaoqiao Free Trade Zone Development | ↗ |
| SERIES COther financing | Sep 2021 | $108M | $432M | CCB International · China Everbright Limited · Co-Stone Capital · GL Ventures | — |
| SERIES BOther financing | Mar 2020 | $60M | $240M | Hillhouse Capital | ↗ |
| SERIES AOther financing | Mar 2018 | $0 | — | Longevity Fund | ↗ |
Growth signals
IASO Biotherapeutics website traffic
Latest recorded traffic for IASO Biotherapeutics is 4.3K monthly website visits, up 115% over the last three months. IASO Biotherapeutics's team grew 11.1% over the past year.
Hiring
Open positions at IASO Biotherapeutics
Current openings linked to this company in Dealroom.
Comparisons
IASO Biotherapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
IASO Biotherapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
16 investors on IASO Biotherapeutics's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where IASO Biotherapeutics has talent and traffic
team presence
In the news
Latest news about IASO Biotherapeutics
Recent press, funding announcements, and product moves mentioning IASO Biotherapeutics — open to read from the original sources.
Market sentiment
What the market is saying about IASO Biotherapeutics
An AI-synthesized read of the highest-engagement posts about IASO Biotherapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See IASO Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.